Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Amazon Great Indian Festival 2020 - Electronics

| More

Company Update - Dr Reddy's Laboratories - ICICI Securities

Posted On: 2020-09-18 06:35:43

Dr Reddy's (DRL) has announced the settlement of its Revlimid capsules (Lenalidomide) patent litigation with Celgene [Bristol Myers Squibb (BMS)] in the US. This makes DRL the third player after Natco and Alvogen to sign a settlement agreement with the innovator for gRevlimid. Under the terms of the settlement, Celgene will provide DRL with a license to sell generic volume-limited amounts of gRevlimid capsules in the US after Natco's launch in March 2022 subject to regulatory approval. This limited volume constraint will be applicable till January 31, 2026 post which DRL will be able to sell the drug in the US without any volume limitations whatsoever. The oncology drug, indicated for treatment of multiple myeloma, had annual US sales of US$9 billion in CY19 as per BMS report.

Valuation & Outlook

The outcome of the company's gRevlimid litigation was one of the key monitorables for DRL due to the sheer opportunity size of the product. We believe this product is likely to remain a limited competition product. As per the agreement, DRL will be restricted to single digit market share in the first year. We expect this to grow to 12% share in the final year (January 2026). Due to uncertainty about the settlement timeline we had not modelled for this opportunity earlier. However, with launch certainty coming in and assuming DRL's gRevlimid launch in October 2022, we expect NPV of Rs. 510 for DRL. Also, we remain positive on the company, banking on the management's focus on simultaneous launches across geographies and segments besides realignment of R&D spend towards - Global Generics, Biosimilars and PSAI segment. Strong FCF generation, healthy balance sheet are some legacy strongholds for the company. We believe efforts taken in the last few quarters are sustainable and should support stable performances, going ahead. We maintain BUY and arrive at a target price of Rs. 5710, which includes base business value of ~Rs. 5200 (26x FY22E EPS of Rs. 200) + Rs. 510 for NPV of gRevlimid.

For details, click on the link below:

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.5326.7 as compared to the previous close of Rs. 4826.6. The total number of shares traded during the day was 637039 in over 51453 trades.

The stock hit an intraday high of Rs. 5497 and intraday low of 4951.05. The net turnover during the day was Rs. 3354640287.

Source: Equity Bulls

Click here to send ur comments or to

Amazon Great Indian Festival 2020 - Mobiles

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Maintain ADD on L&T Infotech - Growth progression continues - HDFC Securities

Cipla Ltd - Launch of generic Nintedanib - Angel Broking

Britannia Industries Ltd - Q2 FY21 Result Update - YES Securities

Hindustan Unilever Ltd - Q2 FY21 Result Update - YES Securities

CCL Products Ltd - Q2 FY21 Result Update - YES Securities

Specialty chemicals - Price trend in Aug-20 - ICICI Securities

Hindustan Unilever - Willingness (necessity?) to sacrifice gross margins to drive growth - ICICI Securities

Britannia Industries - In-home consumption tailwind starts to taper-off - ICICI Securities

Balkrishna Industries - Quarter ends on a strong note - ICICI Securities

Refining & marketing - Diesel cracks: Light at the end of the tunnel? - ICICI Securities

Mahindra CIE Automotive - Resilient margin performance - ICICI Securities

Kajaria Ceramics - Q2FY21 Result Update - ICICI Securities

Hindustan Unilever - Q2FY21 Result Update - ICICI Securities

Castrol India - Initiating Coverage - Compelling Valuation & Counting on Dividend Support - Reliance Research

Reliance Research - R Long Short - Mahindra & Mahindra Financial Services : Directional Long

Kajaria Ceramics - Q2FY21 First Cut - ICICI Securities

Quant Pick - Larsen & Toubro - ICICI Securities

Hindustan Unilever - Q2FY21 First Cut - ICICI Securities

Hindustan Zinc - Q2FY21 First Cut - ICICI Securities

Dhanuka Agritech - Buy back - Angel Broking

Equitas SFB IPO - Day 1 Subscription - Angel Broking

Dr. Reddy's lab relaunch of OTC product - Angel Broking

Hindustan Unilever Ltd - Q2FY21 Results - Angel Broking

Hindustan Unilever Ltd - Q2FY21 Results - YES Securities

Maintain BUY on ACC - Strong cost controls cushion earnings - HDFC Securities

Equitas Small Finance Bank (ESFB) - Subscribe - YES Securities

Granules India - Q2FY2021 results - Angel Broking

Sunteck Realty - Acquisition of 50 acres - Angel Broking

Maintain BUY on Oberoi Realty - Sharp recovery - HDFC Securities

L&T bidding for rail corridor - Angel Broking

Maintain REDUCE on L&T Technology Services - Recovery priced in - HDFC Securities

India IT Services - Thematic - Rising 5G Adoption to Industrialize Digital Services & Connectivity - Reliance Securities

L&T Technology Services - Q2FY21 Result - Angel Broking

L&T Technology Services - 'Multiple' headwinds - ICICI Securities

HDFC Life Insurance Company - Recovery well on track post Covid-19 dip - ICICI Securities

ACC - Strong execution - third time in a row - ICICI Securities

Tata Communications - Keeping faith on sales funnel for revenue growth - ICICI Securities

Hatsun Agro Products - Healthy revenues; strong margins - ICICI Securities

Amber Enterprises Ltd - Business Update Call - YES Securities

Key Takeaways from Q2FY21 earnings call of Shoppers Stop - YES Securities

CSB Bank Q2 FY21 - Not Rated - YES Securities

Britannia Industries 2QFY21 results - YES Securities

HDFC Life Insurance - Q2FY21 Results - YES Securities

ACC Ltd - Q3CY20 Results - YES Securities

IPO Review - Equitas Small Finance Bank - ICICI Securities

Rallis India - Q2FY21 First Cut - ICICI Securities

ACC Ltd - Q3CY20 First Cut - ICICI Securities

Equitas Small Finance Bank Limited - Strongly developing from a microfinance to small bank... - Geojit

Britannia Industries - Q2FY21 Results - Angel Broking

Rallis India - Q2FY21 Results - Angel Broking

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019